Literature DB >> 32113877

Catamenial acute intermittent porphyria managed with GnRH analogs and estrogen and progesterone add-back therapy.

Anshita Aggarwal1, Bindu Kulshreshtha2.   

Abstract

BACKGROUND: Catamenial precipitation of attacks of acute intermittent porphyria (AIP) is commonly treated with Gonadotropin-releasing hormone analogs (GnRHas). However, this leads to various adverse effects that may necessitate 'add-back' therapy with estrogen. The literature on the efficacy and safety of such therapy is scarce. CASE: A 15-year-old lady presented to us with recurrent catamenial attacks of AIP. GnRHa therapy leads to near-complete amelioration of the episodes but her bone density worsened as an adverse effect. To circumvent this, low-dose estrogen was added to her regimen as an 'add-back' therapy, which was later coupled with cyclical progesterone. She continues to do well on this regimen, with no new episodes. SUMMARY AND
CONCLUSION: GnRHa therapy with estrogen 'add-back' is an attractive option for treating catamenial AIP episodes.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32113877     DOI: 10.1016/j.jpag.2020.02.009

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  1 in total

1.  Acute Intermittent Porphyria in Prepubertal Child-diagnostic and Therapeutic Challenges in India: A Case Report and Literature Review.

Authors:  Ankita Goel Sharma; Kaveri Pandit; Shalu Gupta; Virendra Kumar
Journal:  Indian J Crit Care Med       Date:  2022-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.